About
The IVECAT group (Innovation in VEsicles and Cells for Application in Therapy) was founded in February 2002, when Francesc E Borràs joined the Immunology Laboratory at the Germans Trias i Pujol University Hospital on the Can Ruti Biomedical Campus, in Badalona. From initial studies on dendritic cells, the group shifted its basic research to "cell-free" models and concentrating on extracellular vesicles as therapeutic players. This research has the ultimate goal of transferring knowledge to Society. To bring this about, the scientific interests of the research group focus on two priority areas of research.
- Development of new strategies for the improvement in the objective diagnosis of diseases/pathologies
- Research in the field of preventive and therapeutic cell & "Cell-free" advanced therapies for immunomodulation and regenerative medicine
The IVECAT group is included within the REMAR Group (from the name in Catalan, REcerca en Malalties d'Afectació Renal, or Kidney Related Diseases Research Group) is a multidisciplinary group including more than 25 professionals from the Germans Trias University Hospital (HUGTP) and the IGTP - including doctors, biologists, veterinarians, biochemists and biotechnologists. The group was recognized as an emerging group (2014SGR804) and as a Pre-consolidated group (2017SGR301) by the Government of Catalonia.
IVECAT carries out projects both in conjunction with REMAR and independently.
Publications
Members of the Group
Francesc E Borràs(ELIMINAR), Group Leader
Marcella Franquesa Bartolome(ELIMINAR), Principal Investigator
Marta Clos Sansalvador(ELIMINAR), Pre-doctoral Student
Sergio Garcia Garcia(ELIMINAR), Pre-doctoral Student
Miriam Moron Font(ELIMINAR), Nurse/Technician
Research lines
1. Non-invasive Biomarkers
PI: Francesc E. Borràs & Marcella Franquesa
This line of research has a clear translational vocation aiming to improve the quality of life of patients, defining new approaches to avoid or reduce the need on invasive techniques such as biopsies. In this regard, the group is developing several studies to define these new strategies in diverse pathological processes, including renal fibrosis, polycystic kidney disease, dialysis complications, among other pathologies.
Related Projects: PI19/00837, CI19/00048
2. Mesenchymal Stem Cells
PIs: Marcella Franquesa & Francesc E. Borràs
This line of research derives from the interest of our group in the development of basic research projects with a medium-long term translational vision. In this regard, the group has developed in recent years different funded proposals in order to explore more deeply the therapeutic potential of cell therapy (such as mesenchymal stem cells or regulatory B cells) and new approaches. of "cell-free" therapies, including harnessing of extracellular vesicles.
Related Projects: PI20/00097, RED2018-102411-T, PI17/00335, SAF2015-71231-REDT
Research Projects
Size-exclusion chomatography (SEC) isolated MSC-derived Extracellular Vesicles to pReVEnT the progression of chronic kidney disease- SERVET
PI: Marcella Franquesa
Funding Agency: Instituto de Salud Carlos III
Reference: PI20/00097
Start date: 01/01/2021
End date: 31/12/2023
Urine extracellular vesicles and graft elastography: Combining molecular and imaging techniques for the non-invasive diagnosis of chronic kidney graft dysfunction (EV-mage)
PI: Francesc E. Borràs; Javier Juega
Funding Agency: Instituto de Salud Carlos III
Reference: PI19/00837
Start date: 01/01/2020
End date: 31/12/2022
Fibrokit - Urine Extracellular Vesicles based diagnosis for Non-invasive monitoring of renal dysfunction and fibrosis grade
PI: Francesc E Borras
Funding Agency: Obra Social Fundación la Caixa
Reference: CI19/00048
Start date: 01/01/2020
End date: 31/12/2021
News
Células madre mesenquimales revelan mecanismos de funcionamiento de las células B reguladoras independientes de interleucina 10 para su identificación y monitorización
Investigadores del grupo REMAR-IVECAT ("Investigación en Enfermedades de Afectación Renal" e "Innovación en Vesículas y Células para la Aplicación en Terapia"), del Instituto de Investigación Germans Trias i Pujol (IGTP), identifican vías moleculares de las células B reguladoras esenciales para su aplicación terapéutica. En su reciente artículo publicado en Frontiers in Immunology, el uso de celulas madre mesenquimales ha permitido discernir las moléculas esenciales para la monitorización de células B reguladoras en trasplante renal.
Carbohidratos para dirigir las vesículas extracelulares de células madre al endotelio
Investigadores del grupo IVECAT (Innovación en Vesículas y Células para la Aplicación enTterapia), del Instituto de Investigación Germans Trias i Pujol (IGTP), revelan nuevas facetas de la biología de las vesículas extracelulares para avanzar en su aplicación terapéutica. En un artículo publicado en International Journal of Molecular Sciences, han descrito la importancia de las glicosilaciones por la interacción de las vesículas extracelulares de células madre mesenquimales con células endoteliales.
Contact
Francesc E. Borràs (Principal Investigator)
(+34) 93 033 05 26